C3 and hepatocellular carcinoma: To understand immunotherapy efficiency in our defined C1, C2, and C3 subsets, we also analyzed the expression of chemokines and chemokine receptor genes and found remarkable differences in expression profiles across these three subtypes, which might provide clearer guidance for the application of immune targeted therapy in HCC patients.